Daily Anesthesiology Research Analysis
Analyzed 106 papers and selected 3 impactful papers.
Summary
Today’s most impactful anesthesiology-related research spans translational disaster/critical care therapeutics, perioperative neuromodulation for analgesia, and health-systems optimization for organ donation. A randomized large-animal study suggests cilastatin may mitigate crush syndrome–related kidney failure; a blinded RCT shows taVNS reduces postoperative pain and opioid use; and a national geospatial cohort quantifies how expanding donor care units could improve access and system efficiency.
Research Themes
- Translational therapeutics for critical illness (crush syndrome, AKI mitigation)
- Perioperative neuromodulation and opioid-sparing analgesia
- Geospatial health-systems optimization for organ donation
Selected Articles
1. Efficacy of cilastatin sodium in a translational large animal crush syndrome model.
In a blinded, randomized large-animal model of crush syndrome, cilastatin enhanced measured GFR (iohexol clearance), lowered creatinine and histopathologic renal injury, reduced the need for hyperkalemia treatment, and increased AKI recovery likelihood. As an FDA-approved megalin inhibitor (for another indication), cilastatin presents a repurposing opportunity for austere settings.
Impact: This is a rigorous translational study demonstrating a potentially practice-changing, repurposable therapy for crush syndrome—a high-mortality condition encountered in disasters and conflict zones—with direct relevance to critical care anesthesiology.
Clinical Implications: If validated in humans, early cilastatin could reduce AKI severity and hyperkalemia burden after crush injuries, lowering resource needs in austere environments and improving survival. Protocolized integration into disaster response and military critical care should be explored.
Key Findings
- Cilastatin increased measured GFR (iohexol clearance) and reduced serum creatinine versus control after crush injury.
- Histopathologic kidney damage decreased, and animals were more likely to recover from AKI with cilastatin.
- Need for hyperkalemia treatment was reduced; urinary myoglobin excretion increased, suggesting altered toxin handling.
Methodological Strengths
- Randomized, blinded allocation with protocolized 48-hour critical care in a large-animal model.
- Objective renal endpoints including repeated measured GFR (iohexol clearance) and histopathology.
Limitations
- Preclinical animal model limits direct generalizability to humans.
- Single timing (30 minutes post-injury) and setting; survival and long-term outcomes not fully characterized.
Future Directions: Conduct phase 1/2 clinical trials to assess safety, dosing, and efficacy in human crush syndrome; evaluate timing, co-interventions, and outcomes (renal replacement therapy, mortality) in disaster and military settings.
BACKGROUND: Crush syndrome (consisting of hyperkalemia, acidosis, hypocalcemia, and acute kidney injury), is the second-most common cause of death in earthquakes, and a frequent cause of critical illness after burn, blast, and prolonged immobility. No specific treatment exists; supportive treatment is burdensome, contributing to deaths in austere environments, especially disasters and conflicts. There is urgent need for specific treatment which reduces burden of care. Crush syndrome is dependent on the renal megalin-dependent endocytic system. We investigated whether cilastatin sodium, a megalin inhibitor which is US Food and Drug Administration-approved for another purpose, has efficacy as a crush syndrome treatment in a highly translational large animal trauma model. METHODS: Anesthetized 40 kg female pigs received blunt muscle injury and 48 h protocolized critical care management. Cilastatin sodium or vehicle was administered 30 minutes after injury in randomized, blinded fashion. Renal function and injury were assessed by repeated quantification of iohexol clearance, serial plasma assessment, and histopathologic analysis. Linear mixed models and Kaplan-Meier analysis were used to assess differences. A power estimate for a clinical trial was performed. RESULTS: Here we show that cilastatin has efficacy to reduce kidney impairment from crush syndrome, resulting in increased measured glomerular filtration rate and reduced creatinine, histopathologic kidney damage, and need for treatment of hyperkalemia. Animals receiving cilastatin excrete more myoglobin in the urine and are more likely to recover from acute kidney injury. The effect size suggests feasibility of future clinical trials. CONCLUSIONS: Cilastatin sodium has efficacy to ameliorate crush syndrome in a translational large animal model These results support further efforts to translate this potential therapy. Crush syndrome occurs when people are crushed under rubble, or by explosions. It is the second-most common cause of death in earthquakes, and frequent in war. Crushing muscle releases a toxin which causes kidney failure and death from excessive blood potassium, which stops the heart. Treatment requires intensive care, which is often not available in disasters and war zones. Using anesthetized pigs with experimental crush syndrome, we found that the drug cilastatin reduced kidney failure and excessive blood potassium, and increased the likelihood of kidney recovery. Because cilastatin is already approved for another purpose, the path to use for treatment is less challenging than for new drugs. These results may pave the way for human trials of a new treatment.
2. Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Pain Relief in Patients Undergoing Elective Laparoscopic Gastrointestinal Tumor Surgery.
In a patient- and assessor-blinded RCT, taVNS reduced 24-hour pain (median −12 vs −5 mm VAS; P<0.001), lowered opioid consumption at 48 and 72 hours, and hastened return of bowel function, without increasing complications or length of stay.
Impact: Demonstrates a noninvasive, opioid-sparing neuromodulation strategy to improve postoperative recovery after oncologic laparoscopy, aligning with enhanced recovery pathways.
Clinical Implications: taVNS could be incorporated into multimodal analgesia protocols to reduce opioids and facilitate gastrointestinal recovery in laparoscopic oncology surgery, pending broader validation and implementation logistics.
Key Findings
- Greater 24-hour VAS pain reduction with taVNS vs control (median −12.0 mm vs −5.0 mm; P<0.001).
- Lower cumulative opioid use at 48 h and 72 h with taVNS (both P≤0.004).
- Shorter time to first flatus (45 h vs 75 h; P<0.001) without differences in complications, LOS, or QoR-15.
Methodological Strengths
- Patient- and assessor-blinded randomized controlled design with trial registration (NCT06763913).
- Clinically meaningful endpoints (pain, opioid use, bowel function) and consistent effects.
Limitations
- Single-center setting and unspecified sample size in abstract limit generalizability and power assessment.
- Short-term outcomes; effects on complications, recovery quality, and long-term function require larger trials.
Future Directions: Multicenter RCTs to define optimal dosing/timing, identify responders, and evaluate cost-effectiveness and implementation within ERAS pathways across surgical populations.
INTRODUCTION: Acute postoperative pain remains prevalent among patients undergoing gastrointestinal tumor surgery. The study was conducted to evaluate the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in alleviating postoperative pain in this population. METHODS: This patient- and assessor-blinded randomized controlled trial was conducted at the Second Affiliated Hospital of Zhejiang University School of Medicine. Eligible participants who underwent elective laparoscopic gastrointestinal tumor surgery were randomly assigned to the taVNS or control stimulation group. Both groups received the stimulation on the day before surgery and the day after surgery. The primary outcome was the change in visual analogue scale (VAS) scores at 24 h postoperatively. RESULTS: The median reduction in VAS scores was 12.0 in the taVNS group, compared with 5.0 in the control stimulation group (median [interquartile range, IQR] 12.0 [10.0-13.3] mm vs 5.0 [2.0-8.0] mm; P < 0.001). Additionally, the taVNS group showed lower cumulative morphine milligram equivalents (MME) at 48 h (median [IQR] 0 [0-5] mg vs 5 [0-10] mg; P = 0.004) and 72 h (median [IQR] 0 [0-5] mg vs 5 [0-10] mg; P = 0.002), and shorter time to first flatus (median [IQR] 45 [40-60] h vs 75 [60-85] h; P < 0.001). The incidence of complications, length of hospital stay, and quality of recovery-15 (QoR-15) scores are similar between groups. CONCLUSION: TaVNS statistically alleviated postoperative pain in patients undergoing gastrointestinal tumor surgery, decreased analgesic requirements, and promoted gastrointestinal function recovery. TRIAL REGISTRATION: NCT06763913.
3. Geographic Accessibility of Deceased Organ Donor Care Units.
Using national donor and hospital datasets (2018–2023), geospatial location-allocation modeling showed that current DCUs cover only 61.9% of brain-dead donors within 180 minutes; adding 38 DCUs within donation service areas could reach 92.7%, while 22 DCUs ignoring boundaries could reach 96.5%.
Impact: Provides quantitative, nationally representative guidance for optimizing DCU placement and cross-boundary transfers to improve donation efficiency and outcomes—key for anesthesiology-led critical care and donor management.
Clinical Implications: Regional organ donation systems could prioritize DCU expansion in acute-care hubs and consider cross-DSA donor transport to maximize timely donor optimization, resource utilization, and potentially transplant outcomes.
Key Findings
- Current 34 DCUs place 61.9% of brain-dead donors within a 180-minute ambulance drive.
- Adding 38 DCUs within DSA boundaries could reach 92.7% of donors; adding 22 DCUs ignoring DSA boundaries could reach 96.5%.
- Heterogeneous DCU adoption and DSA boundaries introduce inefficiencies limiting access.
Methodological Strengths
- Very large, nationally representative cohort with robust geospatial location-allocation modeling.
- Scenario analyses with and without DSA boundaries quantify policy-relevant options.
Limitations
- Modeling assumptions (e.g., 180-minute drive threshold) may not capture all operational constraints and outcome effects.
- Retrospective design; does not directly measure donor/recipient clinical outcomes after DCU transfer.
Future Directions: Prospective implementation studies evaluating DCU expansion and cross-DSA transfers with outcomes (donor stability, organ yield, transplant outcomes), cost-effectiveness, and equity impacts.
IMPORTANCE: Transfers of deceased organ donors from acute care hospitals to specialized donor care units (DCUs) offer operational and outcome advantages; however, current access to DCUs is limited and geographically uneven. Expanding access to DCUs may improve donation system efficiency. OBJECTIVE: To evaluate the geographic distribution of operating DCUs relative to acute care hospitals and explore how to most efficiently operationalize recommendations that a DCU operate in every donation region. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed deceased organ donor and hospital data captured in the Organ Procurement and Transplantation Network and American Hospital Association survey databases from January 1, 2018, to December 31, 2023. Acute-care hospitals and DCUs operating in the continental US and adult (aged ≥18 years) organ donors with brain death managed in acute care hospitals located in 2203 zip codes were included. The data analysis was performed between October 1, 2024, and December 1, 2025. EXPOSURES: Geographic location of organ donor hospitals. MAIN OUTCOMES AND MEASURES: The main outcome was the optimal number of DCUs required to enable transportation of all cohort donors from acute care hospitals to DCUs via ambulance (within a 180-minute drive). The number of additional DCUs needed to operationalize recommendations of a DCU in every donation region was quantified with and without consideration for donation service area boundaries using location-allocation modeling. RESULTS: Between 2018 and 2023, 53 093 deceased donors met the inclusion criteria (mean [SD] age, 44.3 years [15.0]; 60.0% male). Among the cohort, 61.9% of donors were managed in acute care hospitals within driving distance of 34 operating DCUs. In the current system with distinct donation service area boundaries, an additional 38 DCUs were estimated to provide plausible access to 92.7% of donors. If donation service area boundaries were ignored, 22 new DCUs were estimated to provide a referral facility for a larger proportion of donors (96.5%). CONCLUSIONS AND RELEVANCE: This cohort study found that despite their reported advantages and consensus endorsement, heterogeneous adoption of DCUs has left a substantial proportion of deceased donors after brain death more than a 180-minute drive from a DCU. Given inefficiencies introduced by donation service area boundaries, opening additional DCUs in acute care hospitals and donor transport across these existing boundaries may be 2 potential approaches to improve system efficiency and donation outcomes.